An unpublished data from Italy showed that COVID-19 patients may have elevated levels of IFN-γ, which may affect MSCs therapy (Massimo Dominici, University Hospital of Modena and Reggio Emilia, Modena, Italy) (Khoury et al., 2020). Here, IFNG is linked to COVID-19.